董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Robert P. Mauch | 男 | President, Chief Executive Officer and Director | 58 | 925.32万美元 | 9.80 | 2025-11-15 |
| Lorence H. Kim | 男 | Director | 51 | 32.02万美元 | 0.02 | 2025-11-15 |
| Dennis M. Nally | 男 | Director | 72 | 37.54万美元 | 1.14 | 2025-11-15 |
| Frank Clyburn | 男 | Director | 60 | 未披露 | 未持股 | 2025-11-15 |
| Redonda G. Miller | 女 | Director | 58 | 35.15万美元 | 0.16 | 2025-11-15 |
| Werner Baumann | 男 | Director | 62 | 43.56万美元 | 未持股 | 2025-11-15 |
| D. Mark Durcan | 男 | Chair and Director | 64 | 37.50万美元 | 2.08 | 2025-11-15 |
| Lon R. Greenberg | 男 | Director | 75 | 32.27万美元 | 2.13 | 2025-11-15 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Robert P. Mauch | 男 | President, Chief Executive Officer and Director | 58 | 925.32万美元 | 9.80 | 2025-11-15 |
| Pawan Verma | 男 | Chief Data and Information Officer and Executive Vice President | 48 | 未披露 | 未持股 | 2025-11-15 |
| Lazarus Krikorian | -- | Senior Vice President and Chief Accounting Officer | -- | 未披露 | 未持股 | 2025-11-15 |
| Silvana Battaglia | 女 | Chief Human Resources Officer and Executive Vice President | 58 | 532.02万美元 | 2.20 | 2025-11-15 |
| Elizabeth S. Campbell | 女 | Chief Legal Officer and Executive Vice President | 51 | 766.91万美元 | 1.87 | 2025-11-15 |
| Pawan Verma | 男 | Chief Data and Information Officer and Executive Vice President | 49 | 未披露 | 未持股 | 2025-11-15 |
| James F. Cleary | 男 | Chief Financial Officer and Executive Vice President | 62 | 900.40万美元 | 19.44 | 2025-11-15 |
董事简历
中英对照 | 中文 | 英文- Robert P. Mauch
-
Robert P. Mauch，自2024年10月起担任Cencora总裁兼首席执行官，并担任董事会成员。从2022年10月到2024年9月，Mauch先生担任Cencora的执行副总裁兼首席运营官，此前自2007年以来曾在Cencora及其前身担任过多个其他领导职务，包括领导Cencora的分销业务。他是Xcenda，L.L.C.的创始人，这是一家面向制药公司的生命科学商业化和咨询公司，Xcenda，L.L.C.于2007年被Cencora收购。Mauch先生还是卫生经济学和结果研究专业协会、美国管理式护理药房协会和美国药剂师协会的成员，以及费城盟约之家的董事会主席。
Robert P. Mauch has been President and Chief Executive Officer of the Company and a member of the Board since October 2024. Prior to that, he served as Executive Vice President and Chief Operating Officer from October 2022 to September 2024. He served as Group President from February 2019 to September 2022. He served as Group President, Pharmaceutical Distribution & Strategic Global Scing from June 2017 to February 2019. He served as President, AmerisceBergen Drug Corporation from February 2015 to June 2017. Mr. Mauch served as Senior Vice President and Chief Operating Officer, AmerisceBergen Drug Corporation from March 2014 to February 2015. He was Senior Vice President, Operations, AmerisceBergen Drug Corporation from April 2012 to March 2014. He was Senior Vice President of Sales and Marketing, AmerisceBergen Drug Corporation from April 2011 to April 2012. He was Senior Vice President, Alternate Care Sales and Marketing, AmerisceBergen Drug Corporation from May 2010 to April 2011. Mr. Mauch has been employed by the Company or one of its predecessors for over 25 years. - Robert P. Mauch，自2024年10月起担任Cencora总裁兼首席执行官，并担任董事会成员。从2022年10月到2024年9月，Mauch先生担任Cencora的执行副总裁兼首席运营官，此前自2007年以来曾在Cencora及其前身担任过多个其他领导职务，包括领导Cencora的分销业务。他是Xcenda，L.L.C.的创始人，这是一家面向制药公司的生命科学商业化和咨询公司，Xcenda，L.L.C.于2007年被Cencora收购。Mauch先生还是卫生经济学和结果研究专业协会、美国管理式护理药房协会和美国药剂师协会的成员，以及费城盟约之家的董事会主席。
- Robert P. Mauch has been President and Chief Executive Officer of the Company and a member of the Board since October 2024. Prior to that, he served as Executive Vice President and Chief Operating Officer from October 2022 to September 2024. He served as Group President from February 2019 to September 2022. He served as Group President, Pharmaceutical Distribution & Strategic Global Scing from June 2017 to February 2019. He served as President, AmerisceBergen Drug Corporation from February 2015 to June 2017. Mr. Mauch served as Senior Vice President and Chief Operating Officer, AmerisceBergen Drug Corporation from March 2014 to February 2015. He was Senior Vice President, Operations, AmerisceBergen Drug Corporation from April 2012 to March 2014. He was Senior Vice President of Sales and Marketing, AmerisceBergen Drug Corporation from April 2011 to April 2012. He was Senior Vice President, Alternate Care Sales and Marketing, AmerisceBergen Drug Corporation from May 2010 to April 2011. Mr. Mauch has been employed by the Company or one of its predecessors for over 25 years.
- Lorence H. Kim
-
Lorence H. Kim，曾任职Cencora， Inc.。自2022年10月起担任董事会成员，目前是Ascenta Capital的风险合伙人。从2020年9月到2022年12月，他担任Third Rock Ventures的风险合伙人。2014年4月至2020年6月，他担任Moderna， Inc.的首席财务官。2000年7月至2014年4月，他在Goldman， Sachs & Co.担任多个职位，最近担任生物技术投资银行董事总经理兼联席主管。他自2022年7月起担任Revolution Medicines， Inc.的董事，并自2022年2月起担任TD Cowen（前身为Cowen， Inc.）的董事。Kim博士目前是美国红十字会理事会的成员。2014年10月至2020年6月，他曾担任Seres Therapeutics的董事会成员。
Lorence H. Kim,has served on the Board since October 2022 and currently is a Venture Partner at Ascenta Capital. He served as a Venture Partner at Third Rock Ventures from September 2020 to December 2022. He served as Chief Financial Officer of Moderna, Inc. from April 2014 to June 2020. From July 2000 to April 2014, Dr. Kim held a number of positions at Goldman, Sachs & Co., most recently as Managing Director and Co-Head, Biotechnology Investment Banking. Dr. Kim has served as a director of Revolution Medicines, Inc., since July 2022, and has served as a director of TD Cowen (formerly known as Cowen, Inc. and now a subsidiary of TD Bank, N.A.) since February 2022. Dr. Kim is currently a member of the American Red Cross Board of Governors. He previously served as a member of the Board of Directors of Seres Therapeutics, Inc. from October 2014 to June 2020. - Lorence H. Kim，曾任职Cencora， Inc.。自2022年10月起担任董事会成员，目前是Ascenta Capital的风险合伙人。从2020年9月到2022年12月，他担任Third Rock Ventures的风险合伙人。2014年4月至2020年6月，他担任Moderna， Inc.的首席财务官。2000年7月至2014年4月，他在Goldman， Sachs & Co.担任多个职位，最近担任生物技术投资银行董事总经理兼联席主管。他自2022年7月起担任Revolution Medicines， Inc.的董事，并自2022年2月起担任TD Cowen（前身为Cowen， Inc.）的董事。Kim博士目前是美国红十字会理事会的成员。2014年10月至2020年6月，他曾担任Seres Therapeutics的董事会成员。
- Lorence H. Kim,has served on the Board since October 2022 and currently is a Venture Partner at Ascenta Capital. He served as a Venture Partner at Third Rock Ventures from September 2020 to December 2022. He served as Chief Financial Officer of Moderna, Inc. from April 2014 to June 2020. From July 2000 to April 2014, Dr. Kim held a number of positions at Goldman, Sachs & Co., most recently as Managing Director and Co-Head, Biotechnology Investment Banking. Dr. Kim has served as a director of Revolution Medicines, Inc., since July 2022, and has served as a director of TD Cowen (formerly known as Cowen, Inc. and now a subsidiary of TD Bank, N.A.) since February 2022. Dr. Kim is currently a member of the American Red Cross Board of Governors. He previously served as a member of the Board of Directors of Seres Therapeutics, Inc. from October 2014 to June 2020.
- Dennis M. Nally
-
Dennis M. Nally于2020年1月加入董事会。2009年至2016年，他担任普华永道网络协调与治理实体普华永道会计师事务所主席。2002年至2009年，他担任美国董事长兼高级合伙人。 普华永道会计师事务所。 他于1974年加入普华永道会计师事务所（PricewaterhouseCoopers LLP），并于1985年成为合伙人，在组织内担任多个领导职务，包括国家战略计划总监，审计和业务咨询服务负责人以及执行合伙人。 Nally先生是Morgan Stanley and Globality，Inc.的董事会成员。
Dennis M. Nally,Senior Advisor of SPGI since November 2024;Former President and CEO of SPGI from 2013 to November 2024 and Director of SPGI since 2013;Joined Citigroup Inc. (Citigroup) in 1985 and during his tenure served in senior leadership positions including Chief Operating Officer of Citibank, N.A. from 2010 to 2011, Chairman and CEO of Citigroup Japan from 2004 to 2010, Chief Auditor of Citigroup from 2000 to 2004, and positions of increasing responsibility in Latin America;Member of the Boards of Directors of the UN Global Impact, Japan Society and National Bureau of Economic Research;Member of the Advisory Board of the Federal Deposit Insurance Corporation's Systemic Resolution Advisory Committee.Educational:Claremont McKenna College, Bachelor's Degree;Wharton School at the University of Pennsylvania, Master of Business Administration. - Dennis M. Nally于2020年1月加入董事会。2009年至2016年，他担任普华永道网络协调与治理实体普华永道会计师事务所主席。2002年至2009年，他担任美国董事长兼高级合伙人。 普华永道会计师事务所。 他于1974年加入普华永道会计师事务所（PricewaterhouseCoopers LLP），并于1985年成为合伙人，在组织内担任多个领导职务，包括国家战略计划总监，审计和业务咨询服务负责人以及执行合伙人。 Nally先生是Morgan Stanley and Globality，Inc.的董事会成员。
- Dennis M. Nally,Senior Advisor of SPGI since November 2024;Former President and CEO of SPGI from 2013 to November 2024 and Director of SPGI since 2013;Joined Citigroup Inc. (Citigroup) in 1985 and during his tenure served in senior leadership positions including Chief Operating Officer of Citibank, N.A. from 2010 to 2011, Chairman and CEO of Citigroup Japan from 2004 to 2010, Chief Auditor of Citigroup from 2000 to 2004, and positions of increasing responsibility in Latin America;Member of the Boards of Directors of the UN Global Impact, Japan Society and National Bureau of Economic Research;Member of the Advisory Board of the Federal Deposit Insurance Corporation's Systemic Resolution Advisory Committee.Educational:Claremont McKenna College, Bachelor's Degree;Wharton School at the University of Pennsylvania, Master of Business Administration.
- Frank Clyburn
-
Frank Clyburn，自2024年10月起担任董事会成员。从2022年2月到2024年2月，他担任International Flavors & Fragrances Inc.的执行董事兼首席执行官。此前，他曾担任Merck & Co., Inc.（“Merck”）的执行副总裁兼人类健康总裁（从2021年3月到2022年1月）。从2008年到2021年，他在默克公司担任多种其他领导职务，包括领导公司的肿瘤学和市场准入业务。2004年至2008年，他担任赛诺菲安万特肿瘤学和内科副总裁，1994年以来，他担任赛诺菲安万特及其前身公司的各种职务。Clyburn先生自2024年8月起担任Revolution Medicines， Inc.的董事，此前曾担任DuPont de Numours， Inc.的董事会成员（2019年至2022年）。
Frank Clyburn,has served on the Board since October 2024. He served as Executive Director and Chief Executive Officer of International Flavors & Fragrances Inc. from February 2022 to February 2024. Previously Mr. Clyburn served as Executive Vice President and President, Human Health of Merck & Co., Inc. ("Merck") from March 2021 to January 2022. Mr. Clyburn held a variety of other leadership positions with Merck from 2008 to 2021 including leading the company's oncology and market access business. Prior to Merck, Mr. Clyburn was Vice President, Oncology and Internal Medicine of Sanofi Aventis from 2004 to 2008, holding various positions of increasing responsibility for Sanofi Aventis and its predecessors since 1994. Mr. Clyburn has been a director of Revolution Medicines, Inc. since August 2024 and previously served on the Board of Directors of DuPont de Numours, Inc. from 2019 to 2022. - Frank Clyburn，自2024年10月起担任董事会成员。从2022年2月到2024年2月，他担任International Flavors & Fragrances Inc.的执行董事兼首席执行官。此前，他曾担任Merck & Co., Inc.（“Merck”）的执行副总裁兼人类健康总裁（从2021年3月到2022年1月）。从2008年到2021年，他在默克公司担任多种其他领导职务，包括领导公司的肿瘤学和市场准入业务。2004年至2008年，他担任赛诺菲安万特肿瘤学和内科副总裁，1994年以来，他担任赛诺菲安万特及其前身公司的各种职务。Clyburn先生自2024年8月起担任Revolution Medicines， Inc.的董事，此前曾担任DuPont de Numours， Inc.的董事会成员（2019年至2022年）。
- Frank Clyburn,has served on the Board since October 2024. He served as Executive Director and Chief Executive Officer of International Flavors & Fragrances Inc. from February 2022 to February 2024. Previously Mr. Clyburn served as Executive Vice President and President, Human Health of Merck & Co., Inc. ("Merck") from March 2021 to January 2022. Mr. Clyburn held a variety of other leadership positions with Merck from 2008 to 2021 including leading the company's oncology and market access business. Prior to Merck, Mr. Clyburn was Vice President, Oncology and Internal Medicine of Sanofi Aventis from 2004 to 2008, holding various positions of increasing responsibility for Sanofi Aventis and its predecessors since 1994. Mr. Clyburn has been a director of Revolution Medicines, Inc. since August 2024 and previously served on the Board of Directors of DuPont de Numours, Inc. from 2019 to 2022.
- Redonda G. Miller
-
Redonda G. Miller，曾任职Cencora， Inc.。自2023年1月起担任董事会成员。她曾担任the Johns Hopkins Hospital的总裁（2016年以来）。此前，Miller博士曾担任The Johns Hopkins Hospital and Health System的首席医疗官兼医疗事务高级副总裁（2016年至2017年），以及The Johns Hopkins Hospital and Health System的首席医疗官兼医疗事务副总裁（2009年至2016年）。Miller博士自2006年起担任the Johns Hopkins University医学系副教授。从2021年11月到2022年10月，她担任Invivyd， Inc.（前身为Adagio Therapeutics， Inc.）的非执行董事。Miller博士是Gilchrist Hospice Care， Inc.的董事会成员，也是Turnaround Tuesday Inc.的董事会成员。
Redonda G. Miller,has served on the Board since January 2023. She has served as the President of The Johns Hopkins Hospital since 2016. Previously, Dr. Miller was Chief Medical Officer and Senior Vice President of Medical Affairs of The Johns Hopkins Hospital and Health System from 2016 to 2017, and Chief Medical Officer and Vice President of Medical Affairs of The Johns Hopkins Hospital and Health System from 2009 to 2016. Dr. Miller has been an associate professor in the Department of Medicine at The Johns Hopkins University since 2006. From November 2021 to October 2022, she was a director at Invivyd, Inc. (formerly Adagio Therapeutics, Inc.). Dr. Miller is a member of the Board of Directors of Gilchrist Hospice Care, Inc. and Turnaround Tuesday Inc. - Redonda G. Miller，曾任职Cencora， Inc.。自2023年1月起担任董事会成员。她曾担任the Johns Hopkins Hospital的总裁（2016年以来）。此前，Miller博士曾担任The Johns Hopkins Hospital and Health System的首席医疗官兼医疗事务高级副总裁（2016年至2017年），以及The Johns Hopkins Hospital and Health System的首席医疗官兼医疗事务副总裁（2009年至2016年）。Miller博士自2006年起担任the Johns Hopkins University医学系副教授。从2021年11月到2022年10月，她担任Invivyd， Inc.（前身为Adagio Therapeutics， Inc.）的非执行董事。Miller博士是Gilchrist Hospice Care， Inc.的董事会成员，也是Turnaround Tuesday Inc.的董事会成员。
- Redonda G. Miller,has served on the Board since January 2023. She has served as the President of The Johns Hopkins Hospital since 2016. Previously, Dr. Miller was Chief Medical Officer and Senior Vice President of Medical Affairs of The Johns Hopkins Hospital and Health System from 2016 to 2017, and Chief Medical Officer and Vice President of Medical Affairs of The Johns Hopkins Hospital and Health System from 2009 to 2016. Dr. Miller has been an associate professor in the Department of Medicine at The Johns Hopkins University since 2006. From November 2021 to October 2022, she was a director at Invivyd, Inc. (formerly Adagio Therapeutics, Inc.). Dr. Miller is a member of the Board of Directors of Gilchrist Hospice Care, Inc. and Turnaround Tuesday Inc.
- Werner Baumann
-
Werner Baumann，曾任职Cencora， Inc.。自2023年10月起担任董事会成员。他曾担任Bayer AG的首席执行官兼管理委员会主席（2016年5月至2023年5月退休），并于2020年1月至2023年5月担任首席可持续发展官。Baumann先生于1988年加入Bayer AG，并在公司担任多个职位，责任越来越大，包括在Bayer AG的管理委员会担任首席财务官（2010年至2014年）和首席战略和投资组合官（2014年至2016年）。
Werner Baumann,has served on the Board since October 2023. He previously served as Chief Executive Officer and Chairman of the Board of Management of Bayer AG from May 2016 until his retirement in May 2023, and as Chief Sustainability Officer from January 2020 to May 2023. Mr. Baumann joined Bayer AG in 1988 and held numerous positions of increasing responsibility at the company, including positions on the Board of Management of Bayer AG as Chief Financial Officer from 2010 to 2014 and Chief Strategy and Portfolio Officer from 2014 to 2016. - Werner Baumann，曾任职Cencora， Inc.。自2023年10月起担任董事会成员。他曾担任Bayer AG的首席执行官兼管理委员会主席（2016年5月至2023年5月退休），并于2020年1月至2023年5月担任首席可持续发展官。Baumann先生于1988年加入Bayer AG，并在公司担任多个职位，责任越来越大，包括在Bayer AG的管理委员会担任首席财务官（2010年至2014年）和首席战略和投资组合官（2014年至2016年）。
- Werner Baumann,has served on the Board since October 2023. He previously served as Chief Executive Officer and Chairman of the Board of Management of Bayer AG from May 2016 until his retirement in May 2023, and as Chief Sustainability Officer from January 2020 to May 2023. Mr. Baumann joined Bayer AG in 1988 and held numerous positions of increasing responsibility at the company, including positions on the Board of Management of Bayer AG as Chief Financial Officer from 2010 to 2014 and Chief Strategy and Portfolio Officer from 2014 to 2016.
- D. Mark Durcan
-
D. Mark Durcan，曾在Cencora， Inc.任职。自2015年9月起担任董事会主席，自2023年3月起担任首席独立董事。他曾担任Micron Technology， Inc.的首席执行官兼董事（2012年2月至2017年5月退休）。Durcan先生从2007年6月到2012年2月担任Micron Technology， Inc.的总裁兼首席运营官，从2006年2月到2007年6月担任首席运营官，从1997年6月到2006年2月担任首席技术官。1984年至2006年2月，他担任Micron Technology， Inc.及其子公司的各种其他职位，并从1996年到退休担任官员。他曾担任MWI Veterinary Supply， Inc.的董事（从2014年3月到2015年2月被AmerisourceBergen收购）。Durcan先生自2017年10月起担任Advanced Micro Devices的董事，自2020年4月起担任ASML Holding NV的董事。他曾于2018年4月至2022年4月担任Veoneer的董事，并于2014年至2015年担任Freescale Semiconductor， Inc.的董事。Durcan先生自2017年2月起担任爱达荷州St. Luke's Health System的董事，并自2020年6月起担任Rice大学的董事会成员。他还曾任职于半导体行业协会董事会和技术首席执行官委员会。
D. Mark Durcan,has served on the Board since September 2015 and as the Board's Lead Independent Director since March 2023. From 1984 until his retirement in May 2017, Mr. Durcan held various leadership positions with Micron Technology, Inc., including Chief Executive Officer and director (from February 2012 until May 2017), President and Chief Operating Officer (from June 2007 to February 2012), Chief Operating Officer (from February 2006 to June 2007), and Chief Technology Officer (from June 1997 to February 2006). Mr. Durcan served as a director of MWI Veterinary Supply, Inc. from March 2014 until acquired it in February 2015. Mr. Durcan has served as a director for Advanced Micro Devices since October 2017 and for ASML Holding NV since April 2020. He previously served as a director of Veoneer from April 2018 to April 2022 and Freescale Semiconductor, Inc. from 2014 through 2015. Mr. Durcan has been a director of St. Luke's Health System of Idaho since February 2017 and has served on the Board of Trustees of Rice University since June 2020. He has also served on the Semiconductor Industry Association Board and the Technology CEO Council. - D. Mark Durcan，曾在Cencora， Inc.任职。自2015年9月起担任董事会主席，自2023年3月起担任首席独立董事。他曾担任Micron Technology， Inc.的首席执行官兼董事（2012年2月至2017年5月退休）。Durcan先生从2007年6月到2012年2月担任Micron Technology， Inc.的总裁兼首席运营官，从2006年2月到2007年6月担任首席运营官，从1997年6月到2006年2月担任首席技术官。1984年至2006年2月，他担任Micron Technology， Inc.及其子公司的各种其他职位，并从1996年到退休担任官员。他曾担任MWI Veterinary Supply， Inc.的董事（从2014年3月到2015年2月被AmerisourceBergen收购）。Durcan先生自2017年10月起担任Advanced Micro Devices的董事，自2020年4月起担任ASML Holding NV的董事。他曾于2018年4月至2022年4月担任Veoneer的董事，并于2014年至2015年担任Freescale Semiconductor， Inc.的董事。Durcan先生自2017年2月起担任爱达荷州St. Luke's Health System的董事，并自2020年6月起担任Rice大学的董事会成员。他还曾任职于半导体行业协会董事会和技术首席执行官委员会。
- D. Mark Durcan,has served on the Board since September 2015 and as the Board's Lead Independent Director since March 2023. From 1984 until his retirement in May 2017, Mr. Durcan held various leadership positions with Micron Technology, Inc., including Chief Executive Officer and director (from February 2012 until May 2017), President and Chief Operating Officer (from June 2007 to February 2012), Chief Operating Officer (from February 2006 to June 2007), and Chief Technology Officer (from June 1997 to February 2006). Mr. Durcan served as a director of MWI Veterinary Supply, Inc. from March 2014 until acquired it in February 2015. Mr. Durcan has served as a director for Advanced Micro Devices since October 2017 and for ASML Holding NV since April 2020. He previously served as a director of Veoneer from April 2018 to April 2022 and Freescale Semiconductor, Inc. from 2014 through 2015. Mr. Durcan has been a director of St. Luke's Health System of Idaho since February 2017 and has served on the Board of Trustees of Rice University since June 2020. He has also served on the Semiconductor Industry Association Board and the Technology CEO Council.
- Lon R. Greenberg
-
Lon R. Greenberg，自2013年5月起在Cencora，Inc.董事会任职。他于1996年至2016年1月期间担任UGI公司董事会主席，并担任UGI Utilities，Inc.和AmeriGas Propane的董事，这两家公司均为UGI Corporation的子公司。Greenberg先生自1995年起担任UGI公司的首席执行官，直至2013年4月退休。Greenberg先生在UGI公司任职期间曾担任多个领导职务。格林伯格先生是天普大学董事会成员和费城基金会董事会成员。他还担任天普大学卫生系统董事会主席。他此前曾担任Aqua America，Inc.（现名Essential Utilities, Inc.）、Ameriprise Financial, Inc.、Fox Chase癌症中心以及大费城和新泽西州南部联合之路的董事会成员。
Lon R. Greenberg,has served on the Board since May 2013. He served as Chairman of UGI Corporation's Board of Directors from 1996 until January 2016 and as director of UGI Utilities, Inc. and AmeriGas Propane, both UGI Corporation subsidiaries. Mr. Greenberg served in various leadership positions throughout his tenure with UGI Corporation, most recently serving as Chief Executive Officer from 1995 until his retirement in April 2013. Mr. Greenberg is a member of the Board of Trustees of Temple University and the Board of Directors of The Philadelphia Foundation. He also serves as Chairman of the Board of Directors of Temple University Health System. He previously served as a member of the Boards of Aqua America, Inc. (now known as Essential Utilities, Inc.), Ameriprise Financial, Inc., Fox Chase Cancer Center, and the United Way of Greater Philadelphia and Southern New Jersey. - Lon R. Greenberg，自2013年5月起在Cencora，Inc.董事会任职。他于1996年至2016年1月期间担任UGI公司董事会主席，并担任UGI Utilities，Inc.和AmeriGas Propane的董事，这两家公司均为UGI Corporation的子公司。Greenberg先生自1995年起担任UGI公司的首席执行官，直至2013年4月退休。Greenberg先生在UGI公司任职期间曾担任多个领导职务。格林伯格先生是天普大学董事会成员和费城基金会董事会成员。他还担任天普大学卫生系统董事会主席。他此前曾担任Aqua America，Inc.（现名Essential Utilities, Inc.）、Ameriprise Financial, Inc.、Fox Chase癌症中心以及大费城和新泽西州南部联合之路的董事会成员。
- Lon R. Greenberg,has served on the Board since May 2013. He served as Chairman of UGI Corporation's Board of Directors from 1996 until January 2016 and as director of UGI Utilities, Inc. and AmeriGas Propane, both UGI Corporation subsidiaries. Mr. Greenberg served in various leadership positions throughout his tenure with UGI Corporation, most recently serving as Chief Executive Officer from 1995 until his retirement in April 2013. Mr. Greenberg is a member of the Board of Trustees of Temple University and the Board of Directors of The Philadelphia Foundation. He also serves as Chairman of the Board of Directors of Temple University Health System. He previously served as a member of the Boards of Aqua America, Inc. (now known as Essential Utilities, Inc.), Ameriprise Financial, Inc., Fox Chase Cancer Center, and the United Way of Greater Philadelphia and Southern New Jersey.
高管简历
中英对照 | 中文 | 英文- Robert P. Mauch
Robert P. Mauch，自2024年10月起担任Cencora总裁兼首席执行官，并担任董事会成员。从2022年10月到2024年9月，Mauch先生担任Cencora的执行副总裁兼首席运营官，此前自2007年以来曾在Cencora及其前身担任过多个其他领导职务，包括领导Cencora的分销业务。他是Xcenda，L.L.C.的创始人，这是一家面向制药公司的生命科学商业化和咨询公司，Xcenda，L.L.C.于2007年被Cencora收购。Mauch先生还是卫生经济学和结果研究专业协会、美国管理式护理药房协会和美国药剂师协会的成员，以及费城盟约之家的董事会主席。
Robert P. Mauch has been President and Chief Executive Officer of the Company and a member of the Board since October 2024. Prior to that, he served as Executive Vice President and Chief Operating Officer from October 2022 to September 2024. He served as Group President from February 2019 to September 2022. He served as Group President, Pharmaceutical Distribution & Strategic Global Scing from June 2017 to February 2019. He served as President, AmerisceBergen Drug Corporation from February 2015 to June 2017. Mr. Mauch served as Senior Vice President and Chief Operating Officer, AmerisceBergen Drug Corporation from March 2014 to February 2015. He was Senior Vice President, Operations, AmerisceBergen Drug Corporation from April 2012 to March 2014. He was Senior Vice President of Sales and Marketing, AmerisceBergen Drug Corporation from April 2011 to April 2012. He was Senior Vice President, Alternate Care Sales and Marketing, AmerisceBergen Drug Corporation from May 2010 to April 2011. Mr. Mauch has been employed by the Company or one of its predecessors for over 25 years.- Robert P. Mauch，自2024年10月起担任Cencora总裁兼首席执行官，并担任董事会成员。从2022年10月到2024年9月，Mauch先生担任Cencora的执行副总裁兼首席运营官，此前自2007年以来曾在Cencora及其前身担任过多个其他领导职务，包括领导Cencora的分销业务。他是Xcenda，L.L.C.的创始人，这是一家面向制药公司的生命科学商业化和咨询公司，Xcenda，L.L.C.于2007年被Cencora收购。Mauch先生还是卫生经济学和结果研究专业协会、美国管理式护理药房协会和美国药剂师协会的成员，以及费城盟约之家的董事会主席。
- Robert P. Mauch has been President and Chief Executive Officer of the Company and a member of the Board since October 2024. Prior to that, he served as Executive Vice President and Chief Operating Officer from October 2022 to September 2024. He served as Group President from February 2019 to September 2022. He served as Group President, Pharmaceutical Distribution & Strategic Global Scing from June 2017 to February 2019. He served as President, AmerisceBergen Drug Corporation from February 2015 to June 2017. Mr. Mauch served as Senior Vice President and Chief Operating Officer, AmerisceBergen Drug Corporation from March 2014 to February 2015. He was Senior Vice President, Operations, AmerisceBergen Drug Corporation from April 2012 to March 2014. He was Senior Vice President of Sales and Marketing, AmerisceBergen Drug Corporation from April 2011 to April 2012. He was Senior Vice President, Alternate Care Sales and Marketing, AmerisceBergen Drug Corporation from May 2010 to April 2011. Mr. Mauch has been employed by the Company or one of its predecessors for over 25 years.
- Pawan Verma
Pawan Verma自2015年8月10日起曾担任高级副总裁兼首席信息官。2013年2月至2015年7月，Verma先生在Target Corporation担任各种技术领导职务，在公司架构、电子商务、移动和数字化服务。他最近担任Digital Technology 和API Platforms的副总裁。2011年3月至2013年1月，他担任Convergys公司的电子商务、数字和手机的高级总监。2003年10月至2011年2月，他还担任过在Verizon Wireless各种技术领导职务。
Pawan Verma has served as Executive Vice President, Chief Information and Customer Connectivity Officer since October 2017 and as Senior Vice President and Chief Information Officer from August 2015 to September 2017. From February 2013 to July 2015 Mr. Verma served in various technology leadership roles at Target Corporation within enterprise architecture, e-commerce, mobile, and digital, with his most recent role as Vice President - Digital Technology and API Platforms.- Pawan Verma自2015年8月10日起曾担任高级副总裁兼首席信息官。2013年2月至2015年7月，Verma先生在Target Corporation担任各种技术领导职务，在公司架构、电子商务、移动和数字化服务。他最近担任Digital Technology 和API Platforms的副总裁。2011年3月至2013年1月，他担任Convergys公司的电子商务、数字和手机的高级总监。2003年10月至2011年2月，他还担任过在Verizon Wireless各种技术领导职务。
- Pawan Verma has served as Executive Vice President, Chief Information and Customer Connectivity Officer since October 2017 and as Senior Vice President and Chief Information Officer from August 2015 to September 2017. From February 2013 to July 2015 Mr. Verma served in various technology leadership roles at Target Corporation within enterprise architecture, e-commerce, mobile, and digital, with his most recent role as Vice President - Digital Technology and API Platforms.
- Lazarus Krikorian
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Silvana Battaglia
Silvana Battaglia自2019年1月以来一直担任执行副总裁兼首席人力资源官。在加入公司之前，她于2017年8月至2018年12月在Aramark担任全球薪酬，福利和劳资关系高级副总裁以及高级副总裁。于2011年5月至2017年8月担任全球现场人力资源总监。她还曾在Day＆Zimmerman和Merck Corporation工作。
Silvana Battaglia has been Executive Vice President and Chief Human Resces Officer since January 2019. Prior to joining the Company, she worked at Aramark as Senior Vice President of Global Compensation, Benefits, and Labor Relations from Augt 2017 to December 2018 and as Senior Vice President, Global Field Human Resces from May 2011 to Augt 2017. She also previoly worked for Day & Zimmerman and Merck Corporation.- Silvana Battaglia自2019年1月以来一直担任执行副总裁兼首席人力资源官。在加入公司之前，她于2017年8月至2018年12月在Aramark担任全球薪酬，福利和劳资关系高级副总裁以及高级副总裁。于2011年5月至2017年8月担任全球现场人力资源总监。她还曾在Day＆Zimmerman和Merck Corporation工作。
- Silvana Battaglia has been Executive Vice President and Chief Human Resces Officer since January 2019. Prior to joining the Company, she worked at Aramark as Senior Vice President of Global Compensation, Benefits, and Labor Relations from Augt 2017 to December 2018 and as Senior Vice President, Global Field Human Resces from May 2011 to Augt 2017. She also previoly worked for Day & Zimmerman and Merck Corporation.
- Elizabeth S. Campbell
Elizabeth S. Campbell于2021年9月被任命为Amerisourcebergen Corporation执行副总裁兼首席法律官。她于2020年6月至2021年8月担任高级副总裁和副总法律顾问。在此之前，Campbell女士曾在Amerisourcebergen Corporation法律部门担任各种职务，并承担更多责任，包括担任首席诉讼人和首席合规顾问。
Elizabeth S. Campbell has been Executive Vice President and Chief Legal Officer since September 2021. She served as Senior Vice President and Deputy General Counsel from June 2020 to Augt 2021. Prior to that, Ms. Campbell served in a variety of roles within the Company's legal department with increased responsibility, including serving as Chief Litigator and Chief Compliance Counsel. Ms. Campbell has been employed by the Company for 15 years.- Elizabeth S. Campbell于2021年9月被任命为Amerisourcebergen Corporation执行副总裁兼首席法律官。她于2020年6月至2021年8月担任高级副总裁和副总法律顾问。在此之前，Campbell女士曾在Amerisourcebergen Corporation法律部门担任各种职务，并承担更多责任，包括担任首席诉讼人和首席合规顾问。
- Elizabeth S. Campbell has been Executive Vice President and Chief Legal Officer since September 2021. She served as Senior Vice President and Deputy General Counsel from June 2020 to Augt 2021. Prior to that, Ms. Campbell served in a variety of roles within the Company's legal department with increased responsibility, including serving as Chief Litigator and Chief Compliance Counsel. Ms. Campbell has been employed by the Company for 15 years.
- Pawan Verma
Pawan Verma自2024年10月起担任执行副总裁兼首席数据和信息官。在加入公司之前，他曾于2020年11月至2024年10月任职于大都会人寿，担任执行副总裁兼全球首席信息官。他还曾在富乐客、塔吉特公司和威瑞森通信担任领导职务。
Pawan Verma has been Executive Vice President and Chief Data and Information Officer since October 2024. Prior to joining the Company, he worked at MetLife as Executive Vice President and Global Chief Information Officer from November 2020 to October 2024. He also held leadership roles at Foot Locker, Target Corporation, and Verizon.- Pawan Verma自2024年10月起担任执行副总裁兼首席数据和信息官。在加入公司之前，他曾于2020年11月至2024年10月任职于大都会人寿，担任执行副总裁兼全球首席信息官。他还曾在富乐客、塔吉特公司和威瑞森通信担任领导职务。
- Pawan Verma has been Executive Vice President and Chief Data and Information Officer since October 2024. Prior to joining the Company, he worked at MetLife as Executive Vice President and Global Chief Information Officer from November 2020 to October 2024. He also held leadership roles at Foot Locker, Target Corporation, and Verizon.
- James F. Cleary
James F. Cleary, Jr.自2015年3月起担任执行副总裁，并于2018年11月成为首席财务官。2017年6月至2018年11月，他担任全球商业化服务和动物保健集团总裁。他曾于2015年3月至2017年6月担任MWI Animal Health总裁。在加入公司之前，他从2002年6月起担任MWI Veterinary Supply，Inc.的总裁兼首席执行官。
James F. Cleary has been Executive Vice President since March 2015 and became Chief Financial Officer in November 2018. He served as Group President, Global Commercialization Services & Animal Health from June 2017 to November 2018. He previoly served as President, MWI Animal Health from March 2015 to June 2017. Prior to joining the Company, he was President and Chief Executive Officer of MWI Veterinary Supply, Inc. from June 2002. Mr. Cleary has been employed by the Company or one of its predecessors for over 25 years.- James F. Cleary, Jr.自2015年3月起担任执行副总裁，并于2018年11月成为首席财务官。2017年6月至2018年11月，他担任全球商业化服务和动物保健集团总裁。他曾于2015年3月至2017年6月担任MWI Animal Health总裁。在加入公司之前，他从2002年6月起担任MWI Veterinary Supply，Inc.的总裁兼首席执行官。
- James F. Cleary has been Executive Vice President since March 2015 and became Chief Financial Officer in November 2018. He served as Group President, Global Commercialization Services & Animal Health from June 2017 to November 2018. He previoly served as President, MWI Animal Health from March 2015 to June 2017. Prior to joining the Company, he was President and Chief Executive Officer of MWI Veterinary Supply, Inc. from June 2002. Mr. Cleary has been employed by the Company or one of its predecessors for over 25 years.